ReviewCNS drugs2024
Current Understanding of Compulsive Sexual Behavior Disorder and Co-occurring Conditions: What Clinicians Should Know about Pharmacological Options.
Review in CNS drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Psychotherapy for problematic pornography use: A comprehensive meta-analysis.Journal of behavioral addictions · 2025Pooled it
- Randomised controlled trial of fluoxetine versus naltrexone in compulsive sexual behaviour disorder.BMJ mental health · 2026Trial
- Effects of transcranial direct current stimulation of the right dorsolateral prefrontal cortex on craving and negative emotion regulation in individuals at risk for problematic pornography use: A double-blind, placebo-controlled study.Journal of behavioral addictions · 2025Trial
- Compulsive sexual behavior disorder (CSBD) and problematic pornography use (PPU): A comprehensive, interdisciplinary, and expert-informed narrative review with suggested future directions.Journal of behavioral addictions · 2026Review
- Naltrexone for Acute Management of Compulsive Sexual and Obsessive Symptoms in a Patient With a Neurodevelopmental Disorder.Case reports in psychiatry · 2026Article
- Alcohol and cannabis use severity in relation to compulsive sexual behavior and problematic pornography use in a non-clinical sample: a cross-sectional study.Frontiers in psychiatry · 2026Article
- Women's reproductive mental health: currently available evidence and future directions for research, clinical practice and health policy.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2025Article
- Neurotransmitters crosstalk and regulation in the reward circuit of subjects with behavioral addiction.Frontiers in psychiatry · 2024Review
- Revisiting repetitive behaviors: A case series on compulsive sexual behavior disorder, trichotillomania, non-suicidal self-injury, and binge eating disorder.Industrial psychiatry journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
Abstract
Compulsive sexual behavior disorder (CSBD) has recently been recognized as a psychiatric disorder. Pharmacological treatments for CSBD have received little study and thus have limited empirical support. The main objective of the present work is to review existing literature on the efficacy of different drugs on the symptomatology of CSBD, including the subtype of problematic pornography use (PPU). The main pharmacological approaches to treating CSBD have included opioid antagonists (naltrexone and nalmefene), selective serotonin reuptake inhibitors (paroxetine, citalopram, fluoxetine, and sertraline), mood stabilizers (topiramate), tricyclic antidepressants (clomipramine), serotonin antagonist and reuptake inhibitors (nefazodone), and N-acetylcysteine. Since people with CSBD may experience different co-occurring disorders, these should be considered when choosing the best pharmacological treatment. Pharmacological therapy for CSBD/PPU has been suggested as an adjunct to psychological therapies, which, for the moment, have the most empirical evidence. However, to evaluate the efficacy of most of the drugs presented in this narrative review, data to date have only been available from case studies. Thus, empirical support is scant and generalizability of results is limited, highlighting the need for more research in this area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.